Premium
Application of Systems Pharmacology to Explore Mechanisms of Hepatotoxicity
Author(s) -
Shon J,
Abernethy D R
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.167
Subject(s) - troglitazone , clinical pharmacology , pharmacology , systems pharmacology , drug , safety pharmacology , molecular pharmacology , medicine , drug development , peroxisome , receptor
Advances in systems biology have allowed the development of a highly characterized systems pharmacology model to study mechanisms of drug‐induced hepatotoxicity. In this issue of CPT , Yang et al . describe a model, DILIsym, used to characterize mechanisms of hepatotoxicity of troglitazone. Their modeling approach has provided new insight into troglitazone‐induced hepatotoxicity in humans but is not associated with hepatotoxicity in rats, consistent with preclinical data for this drug. Clinical Pharmacology & Therapeutics (2014); 96 5, 536–537. doi: 10.1038/clpt.2014.167